<DOC>
	<DOCNO>NCT00941499</DOCNO>
	<brief_summary>The goal clinical research study find best combination oxaliplatin , bevacizumab , 5-fluorouracil , leucovorin , cetuximab give patient advanced cancer spread liver . Different combination drug use , safety drug combination also study .</brief_summary>
	<brief_title>Hepatic Arterial Infusion Oxaliplatin + 5FU , Leucovorin , Bevacizumab +/- Cetuximab</brief_title>
	<detailed_description>The Study Drugs : Oxaliplatin design keep new cancer cell grow . 5-fluorouracil design block way cancer cell grow divide , may slow stop growth keep spread throughout body . This may cause cancer cell die . Leucovorin design strengthen effect 5-fluorouracil reduce tumor cell resistance 5-fluorouracil . BECAUSE OF A PHARMACY SHORTAGE OF IV LEUCOVORIN , PATIENTS WILL CONTINUE TREATMENT WITHOUT LEUCOVORIN UNTIL IT BECOMES AVAILABLE . Bevacizumab design block growth blood vessel supply nutrient necessary tumor growth . This may prevent slow growth cancer cell . Bevacizumab long FDA approve treat breast cancer . Cetuximab design prevent slow growth cancer cell block protein inside cancer cell , call epidermal growth factor receptor ( EGFR ) . Study Groups : If find eligible take part study , assign study `` arm '' ( group ) base result screen test . All patient receive oxaliplatin bevacizumab . If doctor think best interest , also receive cetuximab . However , recent study find cetuximab , give alone combination chemotherapy drug , effective give patient colorectal cancer K-RAS mutation . If colorectal cancer test K-RAS gene , also receive cetuximab . Patients normal liver function also receive 5-FU . - If Arm A , receive oxaliplatin , 5-FU , bevacizumab . - If Arm B , receive oxaliplatin , 5-FU , leucovorin , bevacizumab , cetuximab . - If Arm C , receive oxaliplatin bevacizumab . - If Arm D , receive oxaliplatin , bevacizumab , cetuximab . Arm A : All participant receive dose level oxaliplatin bevacizumab . You assign dose level 5-FU base join study . Up 4 dose level 5-FU test . Up 6 participant enrol dose level . The first group participant receive low dose level . Each new group receive high dose group , intolerable side effect see . Arm B : All participant receive dose level oxaliplatin , bevacizumab , leucovorin . You assign combination dose level 5-FU cetuximab base join study . Up 4 combination dose level 5-FU cetuximab test . Up 6 participant enrol dose level . The first group participant receive low dose level . Each new group receive high dose group , intolerable side effect see . Arm C : All participant receive dose level oxaliplatin . You assign dose level bevacizumab base join study . Up 4 dose level bevacizumab test . Up 6 participant enrol dose level . The first group participant receive low dose level . Each new group receive high dose group , intolerable side effect see . Arm D : All participant receive dose level oxaliplatin . You assign combination dose level bevacizumab cetuximab base join study . Up 4 combination dose level bevacizumab cetuximab test . Up 6 participant enrol dose level . The first group participant receive low dose level . Each new group receive high dose group , intolerable side effect see . In group , high tolerable dose study drug combination find , 12 additional patient receive dose level . Additionally , Arm A Arm B , high tolerable dose study drug combination find , 20 additional participant colorectal cancer add Arm A Arm B. Catheter Placement Study Drug Administration : You hospitalize receive study drug combination . On day admission hospital , catheter ( sterile flexible tube place hepatic artery [ blood vessel liver ] local anesthesia ) receive study drug . The catheter place removed cycle . Your doctor explain procedure detail , require sign separate consent form . You must lay bed entire time catheter place . In case , catheter remove right chemotherapy complete . In case , catheter may remain overnight . Therefore , must remain bed catheter remove . Study Drug Administration : Arm A : On day 1 21 day cycle receive oxaliplatin hepatic arterial catheter 2 hour . You receive 5-FU 24 hour hepatic arterial catheter . You receive bevacizumab vein 1 1/2 hour . Arm B : On day 1 21 day cycle receive oxaliplatin hepatic arterial catheter 2 hour 5-FU leucovorin vein 24 hour Days 1 2 cycle ( total 48 hour ) . You receive bevacizumab vein 1 1/2 hour , follow cetuximab vein 1-2 hour . Arm C : On day 1 21 day cycle receive oxaliplatin hepatic arterial catheter 2 hour bevacizumab vein 1 1/2 hour . Arm D : On day 1 21 day cycle receive oxaliplatin hepatic arterial catheter 2 hour receive bevacizumab vein 1 1/2 hour . You also receive cetuximab vein 1-2 hour Day 1 cycle . Study Visits : At study visit , ask drug may receive side effect may . On Day 1 Cycle 1 : - Your medical history record . - You physical exam , include measurement weight vital sign . - Blood ( 4 teaspoon ) draw routine test . - Blood ( 1 teaspoon ) use test blood 's ability clot . - If study doctor think need , ECG . - Women able become pregnant urine pregnancy test . On Day 2 Cycle 1 : -You physical exam , include measurement weight vital sign . On Day 1 Cycles 2 beyond : - You physical exam , include measurement weight vital sign . - Blood ( 4 teaspoon ) draw routine test . - If study doctor think need , ECG . - Women able become pregnant urine pregnancy test . On Day 2 Cycles 2 beyond : -You physical exam , include measurement weight vital sign . At end cycle , blood ( 1 teaspoon ) drawn test blood 's ability clot . At end Cycle 2 every 2-3 cycle , scan check status disease . This may include chest x-ray , CT scan , MRI scan , PET scan and/or PET/CT scan . If study doctor think appropriate , type scan may need perform . The study doctor discus scan , may ask sign separate consent form . Length Study : You may continue receive study drug combination long benefit . You take study disease get bad experience intolerable side effect . Follow-Up : About 6 week last dose study drug , follow test procedure perform : - Blood ( 3 teaspoon ) draw routine test . - You physical exam , include measurement weight vital sign . This investigational study . All study drug FDA-approved commercially available use type cancer : - 5-FU - cancer breast , pancreas , colon/rectum , stomach , type skin cancer ( superficial basal cell carcinoma ) . - Oxaliplatin leucovorin - colorectal cancer . - Bevacizumab - colorectal lung cancer . - Cetuximab - colorectal head/neck cancer . It investigational give study drug together advance cancer . Up 198 participant take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>1 . Patients must histologically confirm cancer metastatic liver metastasis . 2 . Patients refractory standard therapy , relapse standard therapy , standard therapy increase survival least 3 month , unless drug protocol regimen part standard care . 3 . Performance status Eastern Cooperative Oncology Group ( ECOG ) 02 ( Capable self care unable carry work activity ) . Pediatric : performance status Karnovsky ( &gt; 10 ) Lansky ( &lt; 10 ) . 4 . Adequate renal function ( Serum Creatinine &lt; /= 2.0 mg/dL ) . Pediatric : serum creatinine &lt; /= 1.5 mg/dL 2x upper limit normal , age . 5 . Patients stratify liver function test : Normal liver function : Total Bilirubin &lt; /= 3 mg/dL , Alanine aminotransferase ( ALT ) &lt; /= 5 time upper normal reference value . Abnormal liver function : Total bilirubin &gt; 3 mg/dL and/or elevate ALT &gt; 5 x upper limit normal ( ULN ) . If bilirubin &gt; /= 5 mg/dL , fluorouracil ( 5FU ) dose omit . Both group eligible . 6 . Adequate bone marrow function ( Absolute Neutrophil Count ( ANC ) &gt; /=1500 cells/uL ; Platelets ( PLT ) &gt; /= 100,000 cells/uL ) . 7 . At least three week previous cytotoxic chemotherapy day 1 hepatic arterial infusion ( HAI ) infusion . After targeted biologic therapy , 5 halflives three week , whichever short . 8 . All female childbearing age MUST negative urine human chorionic gonadotropin ( HCG ) test unless prior hysterectomy menopause ( define age 55 six month without menstrual activity ) . Patients become pregnant breast feed study . Sexually active patient use effective birth control . 9 . Ability sign inform consent form . Pediatric : age 718 would sign assent , ( &lt; 7 would assent ) , parent guardian would sign consent . 10 . Patients colorectal cancer must agree KRAS mutational status screening , available . If tissue available , patient enter trial , cetuximab arm . 1 . Pregnant female . 2 . Inability complete inform consent process adhere protocol treatment plan followup requirement . 3 . Serious nonhealing wound , ulcer bone fracture . 4 . History abdominal fistula , gastrointestinal perforation intraabdominal abscess within 28 day . 5 . Uncontrolled systemic vascular hypertension ( Systolic blood pressure &gt; 140 mmHg , Diastolic Blood Pressure &gt; 90 mmHg ) . 6 . Uncontrolled intercurrent illness include , limited , ongoing active infection require parental antibiotic , psychiatric illness/social situation would limit compliance study requirement . 7 . Patients already uncompensated liver failure ( i.e . Child Pugh Liver Classification C ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Advanced Cancers</keyword>
	<keyword>Liver</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>Eloxatin</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Avastin</keyword>
	<keyword>Anit-VEGF monoclonal antibody</keyword>
	<keyword>rhuMAb-VEGF</keyword>
	<keyword>5-fluorouracil</keyword>
	<keyword>5-FU</keyword>
	<keyword>Adrucil</keyword>
	<keyword>Efudex</keyword>
	<keyword>Leucovorin</keyword>
	<keyword>Citrovorum</keyword>
	<keyword>Wellcovorin</keyword>
	<keyword>Cetuximab</keyword>
	<keyword>C225</keyword>
	<keyword>Erbitux</keyword>
	<keyword>IMC-C225</keyword>
</DOC>